RT Journal Article
SR Electronic
T1 Characterizing the blood stage antimalarial activity of tafenoquine in healthy volunteers experimentally infected with <em>Plasmodium falciparum</em>
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.21.22282610
DO 10.1101/2022.11.21.22282610
A1 Barber, Bridget E.
A1 Abd-Rahman, Azrin N.
A1 Webster, Rebecca
A1 Potter, Adam J.
A1 Llewellyn, Stacey
A1 Marquart, Louise
A1 Sahai, Nischal
A1 Leelasena, Indika
A1 Birrell, Geoffrey W.
A1 Edstein, Michael D.
A1 Shanks, G. Dennis
A1 Wesche, David
A1 Moehrle, Joerg J.
A1 McCarthy, James S.
YR 2022
UL http://medrxiv.org/content/early/2022/11/22/2022.11.21.22282610.abstract
AB Background The long acting 8-aminoquinoline tafenoquine may be a good candidate for mass drug administration if it exhibits sufficient blood stage antimalarial activity at doses low enough to be tolerated by glucose 6-phosphate dehydrogenase (G6PD) deficient individuals.Methods Healthy G6PD-normal adults were inoculated with Plasmodium falciparum 3D7-infected erythrocytes on day 0. Different single oral doses of tafenoquine were administered on day 8. Parasitemia, and concentrations of tafenoquine and the 5,6-orthoquinone metabolite in plasma/whole blood/urine were measured and standard safety assessments performed. Curative artemether-lumefantrine therapy was administered if parasite regrowth occurred, or on day 48±2. Outcomes were parasite clearance kinetics, pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) parameters from modelling, and dose simulations in a theoretical endemic population.Results Twelve participants were inoculated and administered 200 mg (n=3), 300 mg (n=4), 400 mg (n=2), or 600 mg (n=3) tafenoquine. The parasite clearance half-life with 400 mg or 600 mg (5.4 h and 4.2 h respectively) was faster than with 200 mg or 300 mg (11.8 h and 9.6 h respectively). Parasite regrowth occurred after dosing with 200 mg (3/3 participants) and 300 mg (3/4 participants), but not after 400 mg or 600 mg. Simulations using the PK/PD model predicted that 460 mg and 540 mg would clear parasitaemia by a factor of 106 and 109, respectively, in a 60 kg adult.Conclusions Although a single dose or tafenoquine exhibits potent P. falciparum blood stage antimalarial activity, the estimated doses to effectively clear asexual parasitemia will require prior screening to exclude G6PD deficiency.Main point A single oral dose of tafenoquine is effective against blood stage Plasmodium falciparum infection. However, as the estimated dose to clear asexual parasitaemia is ≥460 mg (in adults), prior screening for glucose 6-phosphate dehydrogenase deficiency will be required.Competing Interest StatementBEB and JSM declare receipt of funding from the Bill and Melinda Gates Foundation and Medicines for Malaria Venture (MMV). GDS declares participation on an Expert Scientific Advisory Committee for MMV and participation on Data Safety Monitoring Boards for multiple MMV sponsored clinical trials. All other authors declare no conflicts of interest.Clinical TrialAustralian and New Zealand Clinical Trials Registry (ACTRN12620000995976)Funding StatementThis study was funded by the Bill and Melinda Gates Foundation (INV-001965). Additional funding support was provided to the Clinical Malaria Group within QIMR Berghofer Medical Research Institute by Medicines for Malaria Venture.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the QIMR Berghofer Medical Research Institute Human Research Ethics Committee (P3646) with mutual recognition by the Australian Departments of Defence and Veterans Affairs Human Research Ethics Committee (194-19). All participants gave written informed consent before enrollment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.AEsadverse eventsG6PDglucose 6-phosphate dehydrogenaseIBSMinduced blood stage malariaMDAmass drug administrationPK/PDpharmacokinetic/pharmacodynamics